SSX8 antibody (AA 21-120)

Catalog No. ABIN760601

The Rabbit Polyclonal anti-SSX8 antibody has been validated for WB, IF (cc), IF (p), ELISA, IHC (fro) and IHC (p). It is suitable to detect SSX8 in samples from Mouse.

Quick Overview for SSX8 antibody (AA 21-120) (ABIN760601)

Target: SSX8 (Synovial Sarcoma, X Breakpoint 8 (SSX8))

Reactivity: Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SSX8 antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-SSX8 Antibody

Binding Specificity: AA 21-120

Cross-Reactivity: Mouse

Predicted Reactivity: Human

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human SSX8

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Expiry Date: 12 months

Target Details for SSX8

Target: SSX8 (Synovial Sarcoma, X Breakpoint 8 (SSX8))

Alternative Name: Ssx8

Background:

Synonyms: Protein SSX8, SSX 8, SSX-8, Synovial sarcoma X breakpoint 8, SSX8_HUMAN.

Background: SSX8 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas.